“Clearly, a KarMMA-3 approval would move Abecma into earlier lines of treatment and be a catalyst to return Abecma to growth by opening up a significant larger patient pool”

In context

“n-time approval of KarMMA-3? Thank you. Sarnit Hirawat: This is Sarnit. Let me just start off with the KarMMA-3 part first. As you know, we have a PDUFA date in December, and that’s all pretty much we can comment on as we continue to work with the regulatory agencies to bring it forward. Adam Lenkowsky: Yes Carter, I’ll just expand on that just a little bit. We mentioned two things in last quarter’s earnings, remember - number one, the S12 maintenance that occurred in June would dampen Q3 sales, and we’re seeing that happen; however, we are also seeing a continued impact from additional BCMA targeted agents, so we knew this was going to be a highly competitive market, putting pressure on growth, and I talked about what we’re doing to really stabilize that business and return it to growth. Clearly, a KarMMA-3 approval would move Abecma into earlier lines of treatment and be a catalyst to return Abecma to growth by opening up a significant larger patient pool; but as Sarnit said, obviously we have to wait to see that approval come. Tim Power: Thanks Adam. Can we go to the next question, please? Operator: Certainly, and that comes from Andrew Baum with Citi. Andrew Baum: Thank you. A question for Adam - many of your predecessors have been scarred trying to get off the bridge onto reimbursed plans. Are you still confident that you’re going to be able to, by the end of this year, get 60% of your CVS insured patients off the bridge onto reimbursed status? Adam Lenkowsky: Yes Andrew, thanks for the question. Conversion is going as we expected. We are focused on pulling through the early access win for Sotyktu at CVS and shifting those patients to commercial product from bridge. As I said last time on the call, it takes about two to three months for”